Opipari Anthony W.
Opipari Anthony W., SR, reported a transaction classified as exercise at Odyssey Therapeutics, Inc. involving 5263.000000 shares. Reported holdings after the transaction were 0.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- May 11, 2026
- Filing date
- May 12, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
Filing warnings
Notes recorded with this filingODTX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- exercise Code M
- Identifier
- 0001193125-26-217584 Series D Warrants (Right to Buy)
- Transaction date
- May 11, 2026 Filed May 12, 2026, 12:30 AM · 1d delay
- Shares
- 5,263 sh Price unknown
- Estimated value
- — Computed from shares × price
- Holdings after
- 0 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-14 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 1
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases. - missing_price-8 points
price_cents is null
Missing price reduces confidence in value-based signals.
- price_cents
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
See Remarks
- F1
The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.…
- F2
The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.…
- F3
The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.…
- F4
The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.…
- F5
The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a ne…
- F6
Pursuant to the terms of the warrants, the Issuer withheld 4 warrant shares to pay the exercise price in connection with the net exercise.
- F7
Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
- F8
Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date…
- F9
Option vests upon the first occurrence of the total market capitalization of the Issuer being equal to or in excess of $1,500,000,000, based on a 5-day volume-weighted average price of a share of Comm…
0 other transactions
0 recent txs